tetano
Editor, Senior Moderator
J Infect Dis. 2012 Jul 30. [Epub ahead of print]
Effectiveness of One Dose of Influenza A (H1N1) 2009 Monovalent Vaccines in Preventing RT-PCR-confirmed H1N1 Infection among School-aged Children in Maine, USA.
Uzicanin A, Thompson M, Smith P, Chaves SS, Foster L, Dube N, Graitcer S, Jackson R, Ferdinands J, Gargiullo P, Mills D, Monto AS, Shay DK; on behalf of the Maine 2009 Influenza A (H1N1) Vaccine Effectiveness Evaluation Group.
Source
Division of Global Migration and Quarantine, and.
Abstract
Background. In late October 2009, school-located pandemic vaccination was initiated in Maine before or concurrent with 2009 pandemic influenza A (H1N1) virus (pH1N1) peak activity.Methods. A case-control evaluation of 2009 H1N1 vaccine effectiveness (VE) was conducted in Cumberland County, Maine schools. A case was a child who had an acute respiratory illness during November 2 -- December 18, 2009, and who tested positive for pH1N1 by real-time reverse transcription polymerase chain reaction (rRT-PCR). For each case, ≥4 event time-matched controls were sampled among classmates present in school during the study period who did not have an influenza-like illness. VE was calculated as (1 - adjusted odds ratio [aOR]) X 100%; aOR was estimated by using weighted logistic regression.Results. After adjusting for a diagnosis of asthma, one dose of 2009 H1N1 vaccine provided 69% protection (95% confidence interval (CI): 13, 89) against rRT-PCR-confirmed H1N1 infection. VE estimates for live attenuated and inactivated vaccine were 81.0% (95% CI: -37, 97), and 57.8% (95% CI: -39, 87), respectively.Conclusions. One dose of monovalent pandemic vaccine provided substantial protection against pH1N1 infection among school-aged children.
PMID:
22850120
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22850120
Effectiveness of One Dose of Influenza A (H1N1) 2009 Monovalent Vaccines in Preventing RT-PCR-confirmed H1N1 Infection among School-aged Children in Maine, USA.
Uzicanin A, Thompson M, Smith P, Chaves SS, Foster L, Dube N, Graitcer S, Jackson R, Ferdinands J, Gargiullo P, Mills D, Monto AS, Shay DK; on behalf of the Maine 2009 Influenza A (H1N1) Vaccine Effectiveness Evaluation Group.
Source
Division of Global Migration and Quarantine, and.
Abstract
Background. In late October 2009, school-located pandemic vaccination was initiated in Maine before or concurrent with 2009 pandemic influenza A (H1N1) virus (pH1N1) peak activity.Methods. A case-control evaluation of 2009 H1N1 vaccine effectiveness (VE) was conducted in Cumberland County, Maine schools. A case was a child who had an acute respiratory illness during November 2 -- December 18, 2009, and who tested positive for pH1N1 by real-time reverse transcription polymerase chain reaction (rRT-PCR). For each case, ≥4 event time-matched controls were sampled among classmates present in school during the study period who did not have an influenza-like illness. VE was calculated as (1 - adjusted odds ratio [aOR]) X 100%; aOR was estimated by using weighted logistic regression.Results. After adjusting for a diagnosis of asthma, one dose of 2009 H1N1 vaccine provided 69% protection (95% confidence interval (CI): 13, 89) against rRT-PCR-confirmed H1N1 infection. VE estimates for live attenuated and inactivated vaccine were 81.0% (95% CI: -37, 97), and 57.8% (95% CI: -39, 87), respectively.Conclusions. One dose of monovalent pandemic vaccine provided substantial protection against pH1N1 infection among school-aged children.
PMID:
22850120
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22850120